domingo, 7 de marzo de 2021

Maximillian White: El "rey" del cannabis medicinal vive en Mallorca

Mallorca es lugar de residencia de multimillonarios, los que hicieron fortuna con los valores tradicionales, y los que la han hecho explotando nuevos —y llamativos— nichos de negocio. Es el caso de Maximillian White, conocido como el magnate del cannabis medicinal. Nacido en Nottingham hace 40 años, es la primera persona que ha amasado una fortuna en una industria que está en pleno florecimiento. Además es una estrella de Instagram, donde suma más de cuatro millones de seguidores. 

La revista ‘Forbes’, interesada en los personajes más acaudalados del planeta, publica en su último número una entrevista a White, ilustrada con fotos tomadas en su casa de Mallorca, en el entorno de la Serra de Tramuntana. 

«Es posible que aún no hayas oído hablar de él, pero este recién llegado a la industria se convertirá en el primer multimillonario del cannabis medicinal a la tierna edad de 40 años», escribe la periodista a modo de introducción. 



Este emprendedor, que reparte su tiempo entre Londres, Dubái y su lujosa residencia de la isla, empezó siendo el dueño de un pub más joven de Inglaterra y ahora, tras un exitoso paso por la industria musical y el mundo inmobiliario, es un magnate del incipiente sector del cannabis medicinal. White es «dueño de cuarenta hectáreas de tierra en Portugal para cultivar cannabis medicinal con una producción estimada de 1.500 millones de euros en valor de mercado al año», escribe Forbes. «Se convertirá en el primer multimillonario de esta industria (sus acciones están valoradas en 3.500 millones de euros)», añade esta publicación. 

White declara que su éxito se debe no tanto a una cuestión de oportunidades sino de personalidad. «Se necesita valor para no importarte ser odiado, escudriñado o el centro de atención. Hay que tener la piel dura, la capacidad de enfrentar las críticas y seguir adelante sin importar el ruido», indica el emprendedor, que exhibe un suntuoso reloj, zapatos exclusivos y joyería. 

De hecho, casi toda la conversación gira en torno a la moda y el diseño, ámbito en el que White se mueve con comodidad hasta el punto de marcar tendencias en @thatboyyouhate, su popular cuenta de Instagram. 

White ha hecho fortuna en la industria del cannabis medicinal al calor de una legislación internacional cada vez más permisiva con la marihuana si se cultiva con fines terapéuticos. (Ver)

 


Cannabis Entrepreneur Makes Between £1 Billion And £3 Billion A Year Selling Medicinal Marijuana 

Max's company is 100 percent dedicated to the pharmaceutical market, so much so that they are currently formulating exclusive strains based on DNA samples. 

He said: "We'll be able to send a swab to your house. And with the information from that swab, we'll be able to know what kind of problems you're going to have within the next 10 years and we'll be able to build a strain of marijuana especially for your body and your ailments over the next 10 years"


"There will be an app that gives us second to second, minute to minute of your sleeping, your heartbeat, how you're dealing with the medication and the information will be sent back to us so we know where we can tweak it at a later date." If you were thinking of popping on a flight over to the Algarve (Covid-dependant, of course), buying a plot of land and growing some weed, it's not going to be quite as easy as that. 

 Max explained: "It's five years in the making. It's not an accident, there's been a lot of hard work there. I've taken a lot of risks that 99.9 percent of people wouldn't take. It's not the same as buying a little allotment." 

Speaking about the money he's bringing in, he added: "If we just look at one of our farms, we're looking to do 108,000 kilos a year. At €5 a gram it's about €540 million". 

"That would be one of our farms. I have three, some bigger. I'd say I'm bringing in anywhere between €2 to €4 billion."(Más)

                                            UK apuesta por los cannabinoides...


The luscious green plants stretch as far as the eye can see. Row after row, lovingly tended in a glasshouse that’s roughly the same size as 34 football pitches.

Thought to be one of the UK’s largest glasshouses, the 45-acre glasshouse in Wissington, Norfolk, sits in an area known for the growing of crops, vegetables and fruit, from peas and beans to tomatoes and strawberries. But this crop is slightly different. Once filled with tomato plants, the glasshouse owned by British Sugar is now home to hundreds of thousands of cannabis plants grown for the pharmaceutical company GW Pharmaceutical.

Carefully cultivated at GW’s research facility in Kent, the plants are reared on an industrial scale in Wissington with high levels of cannabidiol – or CBD – and very little THC (Tetrahydrocannabinol), the psychoactive element commonly associated with marijuana. It makes them perfect for approved and regulated epilepsy drugs. (Más)

Ver todo sobre GW Pharmaceuticals en PHARMACOSERÍAS

sábado, 6 de marzo de 2021

viernes, 5 de marzo de 2021

Ratón de biblioteca: Historia de mis tetas /Jennifer Hayden

 
 
Livraria Lello (Oporto) cumple 115 años



Jennifer Hayden se dio cuenta de que sus pechos podían explicar la historia de su vida cuando le diagnosticaron un cáncer de mama a los cuarenta y tres años. Y así lo reflejó en esta novela gráfica, en la que narra con ingenio, sarcasmo y un sentido del humor hilarante su vida y su historia de superación.

Primero fueron los pequeños protagonistas de una adolescencia acomplejada; más tarde el centro de sus primeras relaciones amorosas; después tuvieron un papel enorme durante la maternidad. Hasta que de golpe comenzaron a representar sentimientos diversos y encontrados, desde la esperanza y el temor, al orgullo y la vergüenza.


La historia de mis tetas llega como una bocanada de aire fresco, con su irresistible mezcla de candor y escepticismo. Esta novela gráfica, carga de simbolismo y humor, hará que lectoras y lectores rían, lloren y se sientan agradecidos por lo que nos depara el día a día.

L’oncòloga Mercedes Alvarado declara que «és important que el pacient senta que no està sol, que veja que hi ha gent que ha patit el mateix que ell o que ella». El còmic autobiogràfic, per tant, a banda de servir com una mena d’alleujament per als autors o autores, també funciona com una ferramenta per a compartir experiències que altra gent pot aprofitar. A més, la majoria d’aquests còmics contenen un comú denominador imprescindible per parlar sobre el càncer: l’humor.(Más)
 

jueves, 4 de marzo de 2021

Top 10 pharma companies 2020


 

With demand for treatments ever increasing, pharmaceutical companies around the world are committed to drive critical innovation to deliver therapies for patients with unmet medical needs and play a pivotal role in the life sciences industry. In 2019, the global pharmaceutical industry continued to grow at a rapid pace, making an estimated $1.3 trillion. As expected, this was largely driven by new product launches such as AbbVie’s Skyrizi and NovartisZolgensma. Slightly down from 2018, the US FDA approved 48 new drugs and biologics in 2019, which still comes in as the third biggest approval class in the past 25 years. The FDA approved an impressive number of generics with a huge 1,171 approvals, breaking its previous record of 971 in 2018. With the tough losses of patents for pharma companies, new product launches are becoming increasingly important.

The Covid-19 pandemic, which was first discovered at the end of 2019, has had an unprecedented impact on the world. Looking forward, communities across the globe are relying on the pharmaceutical industry to create solutions, and many of the companies in the top 10 are involved in the race to produce treatment or prevention measures for the Covid-19 disease. 

In 2020, we expect the effect of the Covid-19 pandemic to become clearer, although since access to healthcare providers has been restricted, the majority of pharma companies in the top 10 have been negatively impacted.


Ranking in at number 10 is American multinational, Amgen. With its “biology-first approach”, Amgen produces innovative medicines and delivers them to 100 countries and regions worldwide. In 2019, Amgen’s revenue fell by 1%, largely caused by a decrease in revenue for Neulasta and Sinsipar/Mimpara which were both impacted by pressure from increased competition. In the earnings call, Amgen’s Chairman and CEO, Robert A. Bradway, confirmed the company is entering a new phase of new product revenue growth.


A staple to the top 10 pharmaceutical companies is French multinational pharmaceutical giant, Sanofi. Sanofi provides healthcare solutions to 170 countries worldwide and has three core focuses: speciality care, vaccines and general medicines. In 2019, Sanofi’s pharmaceutical segment grew by 4% on a year-on-year basis, with a stellar performance from recently launched Eczema treatment Dupixent, which is set for further growth as Sanofi plans to extend its reach to another 89 countries. Looking to the future, Sanofi’s R&D pipeline is in a strong position to produce long-term growth. At the end of July 2020, the R&D programme had 83 projects, including 33 new molecular entities in clinical development (or that have been submitted to the regulatory authorities).


Founded 133 years ago, Bristol-Myers Squibb is a leading global pharmaceutical company that specialises in medicinal advancements in four key areas: oncology, haematology, immunology and cardiovascular disease. The company continued to produce strong growth in 2019, with revenues increasing by 15% year-on-year. In 2019, Bristol-Myers Squibb closed on the acquisition of Celgene, to create a leading biopharmaceutical company. With an extended portfolio of accomplished brands and new product launches, long-term the company is well positioned to achieve steady and sustainable growth.


Headquartered in Osaka, Japanese multinational Takeda is the largest pharmaceutical company in Asia. Following its merger with Shire in early 2019, Takeda has secured its spot in the top 10. The company focuses its efforts in four core areas: oncology, rare diseases, neuroscience, and gastroenterology. Takeda’s geographic footprint is now strongly aligned with global biopharmaceutical industry growth opportunities, with strong presence in the US, Europe and Canada. As an R&D driven company, Takeda is demonstrating its innovation and values in its response to Covid-19 and in positioning itself for stable growth.



AbbVie was created in 2013, when the company separated from Abbott. Employing 47,000 experts, AbbVie tends to drive its R&D efforts towards difficult-to-cure diseases and successfully acquired Allergan in May 2019, strengthening the company’s position in a number of therapeutic areas including immunology, oncology and neuroscience. In 2019, the company’s revenues increased by 2%, with significant clinical and philanthropic achievements.



In the fifth spot is Swiss multinational pharmaceutical company, Novartis.  

Novartis has developed, manufactured and marketed breakthrough medicines for over 250 years. Now with presence in 155 countries across the world, Novartis focuses on innovative medicines as well as generics and biosimilars. In 2019, Innovative Medicines net sales rose by an impressive 8%, driven by pharma key brands Cosentyx, Entresto and Zolgensma. The Oncology division also generated notable growth, with revenues rising by 10%. In 2019, Novartis successfully divested its eye care division, Alcon, with the vision to create a more focused medicines company. Looking ahead, Novartis is set to suffer the greatest number of expiries in 2020 with eight drugs losing their market exclusivity. The company continues to strive for success across all divisions by continually streamlining its services and production platforms.


American pharmaceutical company Merck takes fourth spot as one of the top pharmaceutical companies in the world in 2019. Founded in 1891, Merck is headquartered in New Jersey and focuses on pharmaceuticals, vaccines and animal health. With 71,000 employees worldwide, the company is well known for its contributions to diabetes and cancer care. Full-year 2019 pharmaceutical sales increased by 11% to $41.8 billion. Key growth drivers included Keytruda, Gardasi and Varivax. Looking ahead, Merck continues to streamline its business model in order to invest in breakthrough innovation.


Johnson & Johnson remains in this year's list of the biggest pharmaceutical companies. With headquarters based in New Jersey, Johnson & Johnson develops and produces pharmaceuticals, medical devices and consumer health goods. With a strong performance by key brands Strelara, Darzalex and Imbruvica, Johnson & Johnson’s pharmaceutical division grew by an impressive 4% in 2019. Looking ahead, Johnson & Johnson has a broad portfolio that is well positioned to deliver strong results and long-term growth.

Former number one, leading pharma giant Pfizer takes second place in 2020. Pfizer specialises in the development of medicines and vaccines across a wide range of disciplines including immunology, oncology, cardiology and neurology. The company employees over 88,000 people and delivers its healthcare solutions to over 150 countries across the world. In recent years, Pfizer has dealt with some costly patent expirations including Viagra and Lyrica, and the company expects to be hit by more of these losses this year. In 2019, revenues for the company fell by 1%. A weak performance for consumer health and Upjohn (Pfizer’s off-patent medicine division) was offset by biopharma. Key performers in medicine included Irbrance, Eliquis, Lyrica and Xeljanz. In 2019, Pfizer took bold steps to position the company for sustained growth with the plan to combine Upjohn and Mylan’s strengths, resources and access. This was expected to close in 2020 but this has since been delayed due to the impact of Covid-19.


Roche has taken the top spot in 2020, surpassing Pfizer as the biggest pharmaceutical company in the world. With a workforce of over 90,000 and headquarters based in Basel Switzerland, Roche is at the forefront of oncology, immunology, infectious diseases, ophthalmology and neuroscience. In 2019, sales of Roche’s pharma segment rose by a healthy 16% to $53bn. Growth for the pharma business was driven by the strong uptake of new medicines and product launches which more than compensated for biosimilar competition. Roche’s best-selling drugs included multiple sclerosis medicine Ocrevus, haemophilia medicine Hemlibra and cancer medicines Tecentriq and Perjeta. Looking to the future, Roche is developing its capabilities and building partnerships ready to deliver on the next stage in personalised healthcare and will continue to focus on prescription medicines.(Ver)

miércoles, 3 de marzo de 2021

Jazz Pharmaceuticals compra GW.



 

Jazz Pharmaceuticals paga 6.000 millones de euros para comprar GW, que comercializa fármacos contra la esclerosis múltiple o la epilepsia con derivados de cannabis


Nuevo salto de Jazz Pharmaceuticals. La compañía, que a finales de 2019 selló un contrato milmillonario con Pharma Mar para comercializar el antitumoral Zepzelca en Estados Unidos, ha anunciado que desembolsará un total de 7.200 millones de dólares (unos 6.000 millones de euros al cambio actual) para hacerse con el control de GW Pharmaceuticals

Ver:

Pharma Mar: Goldman Sachs también quiere pescar...en Galicia 

La adquisición se articulará a través de un pago de 200 dólares por acción y la entrega de 20 dólares en acciones. Según asegura Jazz Pharmaceuticals, el acuerdo está previsto que se cierre a lo largo del segundo trimestre y permitirá elevar la facturación de Jazz a un ritmo de doble dígito tras pasar a hacerse con el control de fármacos como el Nabiximoles o el Epidiolex. Se trata de dos de los fármacos estrella de GW Pharmaceuticals.

El primero está dedicado al tratamiento de la esclerosis múltiple y fue primer derivado natural de la planta de cannabis en recibir este tipo de autorización en todo el mundo. El segundo, por su parte, está enfocado al tratamiento de la epilepsia en niños. (Más)